Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

KIDS vs IRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

IRMD Overall Winner 6-Pillar Tally: KIDS 2 – 4 IRMD Matrix Metrics: KIDS 3 – 7 IRMD

As of Nov 19, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas IRMD carries 44.9/100 (HOLD) at $81.26 (33.4x Forward P/E, 32.3% operating margin).

  • Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KIDS vs IRMD
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86
IRMD NASDAQ Head-to-Head Winner
iRadimed Corporation
Surgical & Medical Instruments & Apparatus
$81.26
-1.28% 1D
Market Cap $1.0B
TTM Revenue $89M
Forward P/E 33.4x
Beta / 30D Vol 0.74β · 54% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $84.22 · SMA50: $85.27

6-Pillar Scorecard Institutional Category Breakdown (KIDS 2 – 4 IRMD)

Columns: Metric · KIDS · IRMD
1. Valuation Multiples IRMD
Forward P/E N/M 33.4x
Trailing P/E N/M 43.9x
PEG Ratio N/M 4.46x
EV / Revenue 3.2x 11.7x
2. Growth & Scale KIDS
Revenue Growth (YoY) +18.6% +14.2%
Earnings Growth (YoY) +0.0% +18.3%
TTM Revenue (USD) $264M $89M
Market Cap $850.2M $1.0B
3. Profitability & Quality IRMD
Gross Margin 73.8% 75.5%
Operating Margin -8.2% 32.3%
Net Profit Margin -12.8% 26.9%
Return on Equity (ROE) -9.8% 23.4%
4. Balance Sheet & Cash Flow IRMD
Cash Generation (TTM) $1.1M EBITDA $26M
Cash Flow Margin 0.4% EBITDA Mgn 28.7%
Net Cash / Leverage $12.99 Book/Sh · -9.8% ROE $8.32 Book/Sh · 23.4% ROE
Dividend Yield None (0.00%) 0.97%
5. Options & Positioning IRMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 145.1% (100th %ile) 33.6% (4th %ile)
Put/Call OI Skew N/A 1.00x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 82.0% of Rev ($217M) 43.2% of Rev ($39M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KIDS (3) vs IRMD (7)
Institutional Metric KIDS IRMD Criterion Row Edge
Market Capitalization
Scale
$850.2M $1.0B Larger Scale IRMD
Trailing P/E Ratio
Valuation
N/M 43.9x Lower Multiple IRMD
Forward P/E Ratio
Valuation
N/M 33.4x Lower Multiple IRMD
Revenue Growth (YoY)
Growth
+18.6% +14.2% Higher Growth KIDS
Operating Margin (TTM)
Profitability
-8.2% 32.3% Higher Margin IRMD
Net Profit Margin
Profitability
-12.8% 26.9% Higher Margin IRMD
Return on Equity (ROE)
Capital Efficiency
-9.8% 23.4% Higher ROE IRMD
52-Week Range Position
Momentum
90% ($14–$35) 16% ($76–$108) Stronger Trend KIDS
Beta / 30D Volatility
Risk Regime
0.81β · 108% Vol 0.74β · 54% Vol Lower Realized Risk IRMD
Unified Institutional Score
Composite Signal
45.1 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite KIDS
Trailing 12M Revenue (USD)
Operating Scale
$264M $89M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
73.8% 75.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev 4.46x PEG · 11.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) $26M ($8.32 Book/Sh · 23.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KIDS +43.83 pp
KIDS: +36.37% · IRMD: -7.46%
3M Horizon KIDS +34.24 pp
KIDS: +26.74% · IRMD: -7.5%
6M Horizon KIDS +89.18 pp
KIDS: +76.4% · IRMD: -12.78%
1Y Horizon KIDS +104.55 pp
KIDS: +98.84% · IRMD: -5.71%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KIDS vs IRMD. Trailing 12-month operating profitability (KIDS -8.2% vs IRMD 32.3%) and valuation multiples (KIDS N/M vs IRMD 33.4x Forward P/E) are benchmarked directly in Pillar 4 below.

KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M
IRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$89M
Gross Margin75.5%
Op. Margin32.3%
ROE / Fwd P/E23.4% · 33.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRMD CONSOLIDATION
97d in phase · OBV DISTRIBUTION
Current IV 33.6%
IV Percentile 4th %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published
IRMD Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $1.0B market capitalization and 32.3% operating margin.
OpEx & R&D Reinvestment 43.2% of Rev ($39M)
90D Engineering Disclosures 0 Published

Investor FAQ KIDS vs IRMD Key Questions & Quantitative Answers

As of Nov 19, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas IRMD carries 44.9/100 (HOLD) at $81.26 (33.4x Forward P/E, 32.3% operating margin). Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KIDS leads the Growth & Scale pillar: KIDS posts +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin), compared with IRMD at +14.2% YoY revenue growth and +18.3% YoY earnings growth on $89M TTM revenue (75.5% gross margin, 32.3% operating margin). On trailing 12-month operating scale, KIDS generates $264M in USD-normalized revenue versus $89M for IRMD. In operating R&D and SG&A reinvestment, KIDS deploys 82.0% of Rev ($217M) (0 90-day corporate R&D disclosures) versus 43.2% of Rev ($39M) (0 disclosures) for IRMD.

IRMD screens cheaper on headline valuation multiples. KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin), whereas IRMD trades at 33.4x Forward P/E, 43.9x Trailing P/E, 4.46x PEG, and 11.7x EV/Revenue (28.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KIDS (-9.8% ROE) versus IRMD (23.4% ROE) capital efficiency.

In options market volatility and institutional positioning, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk). By comparison, IRMD carries 33.6% implied volatility (4th %ile, Compressed (<25th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.74β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.